167 related articles for article (PubMed ID: 15168730)
1. Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247.
Shannon KE; Keene JL; Settle SL; Duffin TD; Nickols MA; Westlin M; Schroeter S; Ruminski PG; Griggs DW
Clin Exp Metastasis; 2004; 21(2):129-38. PubMed ID: 15168730
[TBL] [Abstract][Full Text] [Related]
2. A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis.
Harms JF; Welch DR; Samant RS; Shevde LA; Miele ME; Babu GR; Goldberg SF; Gilman VR; Sosnowski DM; Campo DA; Gay CV; Budgeon LR; Mercer R; Jewell J; Mastro AM; Donahue HJ; Erin N; Debies MT; Meehan WJ; Jones AL; Mbalaviele G; Nickols A; Christensen ND; Melly R; Beck LN; Kent J; Rader RK; Kotyk JJ; Pagel MD; Westlin WF; Griggs DW
Clin Exp Metastasis; 2004; 21(2):119-28. PubMed ID: 15168729
[TBL] [Abstract][Full Text] [Related]
3. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.
Reinmuth N; Liu W; Ahmad SA; Fan F; Stoeltzing O; Parikh AA; Bucana CD; Gallick GE; Nickols MA; Westlin WF; Ellis LM
Cancer Res; 2003 May; 63(9):2079-87. PubMed ID: 12727823
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy.
Abdollahi A; Griggs DW; Zieher H; Roth A; Lipson KE; Saffrich R; Gröne HJ; Hallahan DE; Reisfeld RA; Debus J; Niethammer AG; Huber PE
Clin Cancer Res; 2005 Sep; 11(17):6270-9. PubMed ID: 16144931
[TBL] [Abstract][Full Text] [Related]
5. Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist.
Belvisi L; Riccioni T; Marcellini M; Vesci L; Chiarucci I; Efrati D; Potenza D; Scolastico C; Manzoni L; Lombardo K; Stasi MA; Orlandi A; Ciucci A; Nico B; Ribatti D; Giannini G; Presta M; Carminati P; Pisano C
Mol Cancer Ther; 2005 Nov; 4(11):1670-80. PubMed ID: 16275988
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L
Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of metastatic cell colonization in murine lungs and tumor-induced morbidity by non-peptidic Arg-Gly-Asp mimetics.
Hardan I; Weiss L; Hershkoviz R; Greenspoon N; Alon R; Cahalon L; Reich S; Slavin S; Lider O
Int J Cancer; 1993 Dec; 55(6):1023-8. PubMed ID: 7504656
[TBL] [Abstract][Full Text] [Related]
8. A novel RGD antagonist that targets both alphavbeta3 and alpha5beta1 induces apoptosis of angiogenic endothelial cells on type I collagen.
Meerovitch K; Bergeron F; Leblond L; Grouix B; Poirier C; Bubenik M; Chan L; Gourdeau H; Bowlin T; Attardo G
Vascul Pharmacol; 2003 Feb; 40(2):77-89. PubMed ID: 12646396
[TBL] [Abstract][Full Text] [Related]
9. A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy.
Carron CP; Meyer DM; Pegg JA; Engleman VW; Nickols MA; Settle SL; Westlin WF; Ruminski PG; Nickols GA
Cancer Res; 1998 May; 58(9):1930-5. PubMed ID: 9581835
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice.
Kim LS; Huang S; Lu W; Lev DC; Price JE
Clin Exp Metastasis; 2004; 21(2):107-18. PubMed ID: 15168728
[TBL] [Abstract][Full Text] [Related]
11. Single cell tracking assay reveals an opposite effect of selective small non-peptidic α5β1 or αvβ3/β5 integrin antagonists in U87MG glioma cells.
Ray AM; Schaffner F; Janouskova H; Noulet F; Rognan D; Lelong-Rebel I; Choulier L; Blandin AF; Lehmann M; Martin S; Kapp T; Neubauer S; Rechenmacher F; Kessler H; Dontenwill M
Biochim Biophys Acta; 2014 Sep; 1840(9):2978-87. PubMed ID: 24810979
[TBL] [Abstract][Full Text] [Related]
12. Prevention of cancer metastasis in mice with fibronectin-related substances.
Azuma I; Saiki I
Princess Takamatsu Symp; 1994; 24():125-41. PubMed ID: 8983070
[TBL] [Abstract][Full Text] [Related]
13. RGD binding to integrin alphavbeta3 affects cell motility and adhesion in primary human breast cancer cultures.
Georgoulis A; Havaki S; Drosos Y; Goutas N; Vlachodimitropoulos D; Aleporou-Marinou V; Kittas C; Marinos E; Kouloukoussa M
Ultrastruct Pathol; 2012 Dec; 36(6):387-99. PubMed ID: 23181508
[TBL] [Abstract][Full Text] [Related]
14. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials.
Shalinsky DR; Brekken J; Zou H; McDermott CD; Forsyth P; Edwards D; Margosiak S; Bender S; Truitt G; Wood A; Varki NM; Appelt K
Ann N Y Acad Sci; 1999 Jun; 878():236-70. PubMed ID: 10415735
[TBL] [Abstract][Full Text] [Related]
15. An integrin αvβ3 antagonistic modified peptide inhibits tumor growth through inhibition of the ERK and AKT signaling pathways.
Hu L; Wang J; Wang Y; Xu H
Oncol Rep; 2016 Oct; 36(4):1953-62. PubMed ID: 27499314
[TBL] [Abstract][Full Text] [Related]
16. Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.
Walsh C; Tanjoni I; Uryu S; Tomar A; Nam JO; Luo H; Phillips A; Patel N; Kwok C; McMahon G; Stupack DG; Schlaepfer DD
Cancer Biol Ther; 2010 May; 9(10):778-90. PubMed ID: 20234193
[TBL] [Abstract][Full Text] [Related]
17. The anticancer properties and mechanism of action of tablysin-15, the RGD-containing disintegrin, in breast cancer cells.
Deng Z; Chai J; Zeng Q; Zhang B; Ye T; Chen X; Xu X
Int J Biol Macromol; 2019 May; 129():1155-1167. PubMed ID: 30660566
[TBL] [Abstract][Full Text] [Related]
18. Association of alphavbeta3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells.
Duan X; Jia SF; Zhou Z; Langley RR; Bolontrade MF; Kleinerman ES
Clin Exp Metastasis; 2004; 21(8):747-53. PubMed ID: 16035619
[TBL] [Abstract][Full Text] [Related]
19. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer.
Tamamura H; Hori A; Kanzaki N; Hiramatsu K; Mizumoto M; Nakashima H; Yamamoto N; Otaka A; Fujii N
FEBS Lett; 2003 Aug; 550(1-3):79-83. PubMed ID: 12935890
[TBL] [Abstract][Full Text] [Related]
20. R-isomers of Arg-Gly-Asp (RGD) mimics as potent alphavbeta3 inhibitors.
Nagarajan SR; Devadas B; Malecha JW; Lu HF; Ruminski PG; Rico JG; Rogers TE; Marrufo LD; Collins JT; Kleine HP; Lantz MK; Zhu J; Green NF; Russell MA; Landis BH; Miller LM; Meyer DM; Duffin TD; Engleman VW; Finn MB; Freeman SK; Griggs DW; Williams ML; Nickols MA; Pegg JA; Shannon KE; Steininger C; Westlin MM; Nickols GA; Keene JL
Bioorg Med Chem; 2007 Jun; 15(11):3783-800. PubMed ID: 17399986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
